Skip to main content

Table 1 Chemotherapies, immunotherapies, and targeted therapies for metastatic NSCLC

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Type of TherapyAgents/Agent combinations
Traditional Chemotherapies
 Platinum monotherapyCarboplatin, Cisplatin
 Platinum doublet therapy
  With cisplatinDocetaxel, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, Vinorelbine
  With carboplatinDocetaxel, Gemcitabine, Paclitaxel, Pemetrexed, Vinorelbine
 Non-platinum based combination therapiesGemcitabine/Docetaxel, Gemcitabine/Paclitaxel, Gemcitabine/Vinorelbine, Paclitaxel/Vinorelbine, Pemetrexed/Gemcitabine
 Maintenance therapyDocetaxel, Gemcitabine, Pemetrexed
ImmunotherapiesAtezolizumab, Nivolumab, Pembrolizumab
Targeted Therapies
 ALK inhibitorsAlectinib, Brigatinib, Ceritinib, Crizotinib
 Angiogenesis inhibitorsBevacizumab, Ramucirumab
 BRAF inhibitorVemurafenib
 CDK4/6 inhibitorPalbociclib
 EGFR monoclonal antibody inhibitorCetuximab, Necitumumab
 EGFR tyrosine kinase inhibitorsAfatinib, Erlotinib, Gefitinib, Osimertinib
 MEK inhibitorTrametinib
 Other monoclonal antibody inhibitorsIpilimumab, Trastuzumab
  1. ALK anaplastic lymphoma kinase, BRAF Raf isoform B, CDK cyclin dependent kinase, EGFR epidermal growth factor receptor, MEK mitogen activated protein kinase kinase